Ovarian cancer
Results
Phase 3
This trial looked at chemotherapy combined with a monoclonal antibody for ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
Doctors usually treat ovarian cancer with surgery and chemotherapy. They often use the chemotherapy drugs carboplatin and paclitaxel (Taxol).
Bevacizumab (Avastin) is a type of biological therapy called a monoclonal antibody. Researchers hoped that giving bevacizumab as well as chemotherapy may be better than chemotherapy alone.
The aim of this trial was to find out if adding bevacizumab to chemotherapy helps stop ovarian cancer coming back after surgery.
Recruitment start: 13 December 2006
Recruitment end: 16 February 2009
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr T Perren
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
F.Hoffmann-La Roche Ltd (Roche)
Medical Research Council (MRC)
National Institute for Health Research Cancer Research Network (NCRN)
This is Cancer Research UK trial number CRUKE/05/024.
Last reviewed: 1 August 2016
CRUK internal database number: 716
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
